Get an email when this journal's indexing changes
Added to or removed from Scopus, Web of Science, ABDC, DOAJ, FT50, UT Dallas or ONOS. One confirmation click; unsubscribe anytime.
Advances in Cancer Biology - Metastasis is Scopus-indexed (Q2, CiteScore 8.1), WoS ESCI, DOAJ. Published by Elsevier Inc..
Checked against the index lists dated .
ISSN 2667-3940Verify ISSN ↗
Publisher: Elsevier Inc.
Cost to publish: Checking DOAJ for article charges…
| Subject area | Rank | Pctile | Q |
|---|---|---|---|
| Cancer Research | 62 / 233 | 73rd | Q2 |
| Cell Biology | 84 / 289 | 71st | Q2 |
Not listed in: ABDC, ABS / AJG, FT50, UT Dallas, ONOS (subscription), ONOS (APC covered)
Yes — actively indexed in Scopus, coverage 2021–present, best quartile Q2, CiteScore 8.1.
Advances in Cancer Biology - Metastasis is Q2 in Cancer Research (rank 62 of 233) and Q2 in Cell Biology (rank 84 of 289), by CiteScore 2025.
Advances in Cancer Biology - Metastasis is indexed in the Emerging Sources Citation Index, so it may have a Journal Impact Factor in Clarivate's Journal Citation Reports. JCR is paid, so check it for the current value. The closest free measure is its Scopus CiteScore 8.1, which places it in quartile Q2 at the 73rd percentile of its subject. Its SCImago Journal Rank (SJR, a free Scopus-based metric) is 0.855, quartile Q3, with an H-index of 19.
The publisher lists an article processing charge of about US$2,650 for open access (source: OpenAlex). Many journals also publish by the subscription route at no cost to the author, so confirm on the journal's own website.
Advances in Cancer Biology - Metastasis is published by Elsevier Inc. Its ISSN is 2667-3940.
Yes — indexed in the Emerging Sources Citation Index.
Yes — it is an open-access journal, listed in DOAJ.
Advances in Cancer Biology - Metastasis has an h-index of 21 and a 2-year mean of 2.48 citations per paper (OpenAlex). Its Scopus CiteScore is 8.1, quartile Q2. On 2-year citations it ranks #120 of 229 Scopus journals in Cancer Research.
Advances in Cancer Biology - Metastasis published 35 papers in 2025; its busiest recent year was 2022 with 56. 2026* is the year so far.
h-index, i10-index and 2-year mean citedness are open, licence-clear metrics from OpenAlex — not a proprietary impact factor. The subject rank counts only journals that OpenAlex has a figure for; it is not a Scopus or Clarivate ranking. Updated 2026-10-14.
In its latest 90 research articles (2023–2026), authors are most often from Iran (25.6%), India (22.9%) and China (19.3%).
Countries are counted fractionally, so a paper by authors from two countries counts half to each.
Scopus status: Active. 2 retracted papers are recorded (9.9 per 1,000 papers). The Problematic Paper Screener flags 2 of its papers. These are indicators to check, not findings against the journal.
Retractions from OpenAlex; flags from the Problematic Paper Screener (Cabanac, Labbé & Magazinov, CC BY), 2026-09-21 export. A flag marks a paper for a closer look; it is not a finding against the journal.
Index data is curated from public sources (Scopus, Web of Science, ABDC, FT50, UT Dallas, DOAJ). CiteScore and quartiles reflect the latest available Scopus release. Always verify a journal's current status on its official source before submitting.
Comments load as you scroll here.